BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36057520)

  • 21. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
    Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
    Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Will targeted therapies replace chemotherapy?].
    Collignon J; Jerusalem G
    Rev Med Liege; 2012; 67 Spec No():29-36. PubMed ID: 22690483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    CufĂ­ S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting receptor tyrosine kinases in gastric cancer.
    Morishita A; Gong J; Masaki T
    World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
    Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
    Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
    Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK
    Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ErbB inhibitors as neoadjuvant therapy for triple-positive breast cancer: a network meta-analysis.
    Chen D; Jin L; Xu Y; Bhandari A; Wang O
    Am J Transl Res; 2021; 13(11):12129-12140. PubMed ID: 34956441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
    Tchelebi LT; Batchelder E; Wang M; Lehrer EJ; Drabick JJ; Sharma N; Machtay M; Trifiletti DM; Zaorsky NG
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34350378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A; Giordano S
    Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
    Kono K; Mimura K; Fujii H; Shabbir A; Yong WP; Jimmy So A
    Ann Thorac Cardiovasc Surg; 2012; 18(6):506-13. PubMed ID: 23232268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.